CD8A and metabolic dysfunction-associated steatohepatitis: It will be intriguing to see whether the application of N-acetylcysteine is sufficient to restore tumor immunity in NASH-HCC patients and if this may even prevent NASH patients from CD8 T cell mediated liver damage and subsequent tumor development by reintroducing proper CD4-mediated regulation of CD8 T cell responses [107,108].